Racial Disparities in Biomarker Testing, Clinical Trial Participation Affect Outcomes in NSCLC
Results of a retrospective analysis detected racial disparities in rates of biomarker testing and clinical trial participation among patients with NSCLC.
Results of a retrospective analysis detected racial disparities in rates of biomarker testing and clinical trial participation among patients with NSCLC.
Local recurrence increased but overall survival at 10 years similar with omission of RT in older women with HR+ breast cancer.
Understanding causes of death in contemporary patients with prostate cancer is essential for proper survivorship management, according to investigators.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ in their rates of BCG intolerance and recurrence- and progression-free survival, a study found.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
This study examined bladder cancer that developed after radiation for any cancer potentially affecting the organ, not just prostate cancer.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
In a subgroup analysis, neither patient characteristics nor prior treatment history influenced response to a novel intravesical gene therapy for BCG-unresponsive bladder cancer.